Tubulis logo
Startup

Tubulis

See Tubulis's full profile

BOOK A DEMO
Headquarters

Germany

Founded Year

2019

Total Funding

$13.9M

Employees

11 - 50

Status

Active


About Tubulis

Tubulis generates uniquely matched protein-drug conjugates through the combination of novel proprietary technologies and disease-specific biologic insight.

Headquarters

Butenandtstraße 1, 81377 München, Germany


General Information on Tubulis

Brand name Tubulis
Company name Tubulis GmbH
Register number HRB 249942
Website https://tubulis.com/
Founded year 2019
Employees 11 - 50
Founding team

Dominik Schumacher

Jonas Helma-Smets

Contact [email protected]
+4989218074233

Find startup solutions in your specific business context

The INNOSPOT Startup Discovery platform helps you to find the right startup solutions by leveraging the world's most powerful Startup Search Engine analyzing millions of data points.
BOOK A DEMO

Recent News and Activity about Tubulis

FOX 40 WICZ TV (NY) 23.09.2021
Tubulis Establishes Scientific Advisory Board with Leading ADC Drug Development and Oncology Experts

Pamela Trail is a leading expert in oncology research and has more than 30 years of experience in the biotechnology and pharmaceutical industry developing ADCs, immunomodulatory antibodies, bispecific antibodies and small molecules. Between 2017 and 2019, she held the position Chief Scientific Officer at Molecular Partners. Prior, she served as Vice President Oncology Strategy and Program Direction at Regeneron Pharmaceuticals. She also held the ...

Tubulis news
azcentral.com (Arizona) 23.09.2021
Tubulis Establishes Scientific Advisory Board with Leading ADC Drug Development and Oncology Experts | Help Center - The Arizona Republic

Tubulis today announced the formation of a Scientific Advisory Board with the appointment of international industry experts in the development

Market Screener 23.09.2021
Tubulis : Establishes Scientific Advisory Board with Leading ADC Drug Development and Oncology Experts

industry experts in the development of antibody drug conjugates (ADCs) and in-depth knowledge in the therapeutic areas of oncology and hematology. The SAB will provide scientific guidance and advice, working in close collaboration with the Tubulis management team, as the company advances its pipeline of disease-specific protein-drug conjugates towards clinical evaluation. “Attracting these accomplished and highly regarded experts as inaugural ...

Tubulis news